ASIA PACIFIC IMMUNOHISTOCHEMISTRY MARKET FORECAST 2018-2026

ASIA PACIFIC IMMUNOHISTOCHEMISTRY MARKET FORECAST 2018-2026

  • April 2018 •
  • 77 pages •
  • Report ID: 5373304 •
  • Format: PDF
KEY FINDINGS
The immunohistochemistry market in the APAC region is proliferating at a CAGR of 8.18% throughout the forecasting years 2018 to 2026. Growing number of cancer patients and increasing aging populace are key driving reasons for the market in the region.

MARKET INSIGHTS
The Asia Pacific immunohistochemistry market comprises of countries like India, Australia, China, South Korea, Japan, and Rest of APAC.The product segment is bifurcated into antibodies, reagents, equipment, and kits.

The various equipment in the product segment are slide staining systems, tissue microarrays, tissue processing systems, slide scanners, and other equipment’s.The various application in the market are diagnostics and drug testing.

The diagnostics application include cancer, infectious diseases, cardiovascular disease, autoimmune diseases, diabetes mellitus, and nephrological diseases. China holds the colossal share in the APAC region and is expected to sustain its leadership over the forecasting years.

COMPETITIVE INSIGHTS
The companies dominating the market are F. Hoffmann-La Roche Ag, Abcam Plc, Siemens Ag Healthcare, Bio-Rad Laboratories Inc., Perkinelmer Inc., Cell Signaling Technology Inc., Abbott Laboratories, Merck Millipore, Biogenex, Agilent Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., Bio Sb, and Histologix.